Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline O'Leary
Jarushka Naidoo

Showing results (1-10 of 170) with videos related to

Pageof 17
Sort By:
Current Oncology (Toronto, Ont.)|July 28, 2023
Prospective Clinical Trials to Advance the Study of Immune Checkpoint Inhibitor ToxicityChristopher Cluxton, Jarushka Naidoo
Cancer Metastasis Reviews|July 25, 2022
The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancerPhilip Bredin, Jarushka Naidoo
Advances in Experimental Medicine and Biology|December 16, 2015
KRAS-Mutant Lung Cancers in the Era of Targeted TherapyJarushka Naidoo, Alexander Drilon
Lung Cancer (Auckland, N.Z.)|November 10, 2021
Immunotherapy for Stage III NSCLC: Durvalumab and BeyondOrla Fitzpatrick, Jarushka Naidoo
Thoracic Surgery Clinics|April 25, 2020
Principles of Immunotherapy in Non-Small Cell Lung CancerMelinda L Hsu, Jarushka Naidoo
Frontiers in Oncology|July 12, 2019
Immune-Related Adverse Events: A Case-Based ApproachCaoilfhionn Connolly, Kalindi Bambhania, Jarushka Naidoo
The Journal of Clinical Investigation|December 12, 2018
An adapted anti-CTLA4 therapeutic aimed at mitigating the toxicities of checkpoint inhibitionJarushka Naidoo, Arbor Dykema, Franco D'Alessio
European Heart Journal|August 30, 2022
Cardiovascular complications of immune checkpoint inhibitors for cancerFranck Thuny, Jarushka Naidoo, Tomas G Neilan
Current Oncology Reports|May 17, 2020
Checkpoint Inhibitor Pneumonitis: Mechanisms, Characteristics, Management Strategies, and BeyondJoshua E Reuss, Karthik Suresh, Jarushka Naidoo
Cureus|November 29, 2019
Successful Treatment of Scar Pain with Scrambler TherapyMark Yarchoan, Jarushka Naidoo, Thomas J Smith
Pageof 17

Showing results (1-10 of 170) with videos related to

Sort By:
Pageof 17
Current Oncology (Toronto, Ont.)|July 28, 2023
Prospective Clinical Trials to Advance the Study of Immune Checkpoint Inhibitor ToxicityChristopher Cluxton, Jarushka Naidoo
Cancer Metastasis Reviews|July 25, 2022
The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancerPhilip Bredin, Jarushka Naidoo
Advances in Experimental Medicine and Biology|December 16, 2015
KRAS-Mutant Lung Cancers in the Era of Targeted TherapyJarushka Naidoo, Alexander Drilon
Lung Cancer (Auckland, N.Z.)|November 10, 2021
Immunotherapy for Stage III NSCLC: Durvalumab and BeyondOrla Fitzpatrick, Jarushka Naidoo
Thoracic Surgery Clinics|April 25, 2020
Principles of Immunotherapy in Non-Small Cell Lung CancerMelinda L Hsu, Jarushka Naidoo
Frontiers in Oncology|July 12, 2019
Immune-Related Adverse Events: A Case-Based ApproachCaoilfhionn Connolly, Kalindi Bambhania, Jarushka Naidoo
The Journal of Clinical Investigation|December 12, 2018
An adapted anti-CTLA4 therapeutic aimed at mitigating the toxicities of checkpoint inhibitionJarushka Naidoo, Arbor Dykema, Franco D'Alessio
European Heart Journal|August 30, 2022
Cardiovascular complications of immune checkpoint inhibitors for cancerFranck Thuny, Jarushka Naidoo, Tomas G Neilan
Current Oncology Reports|May 17, 2020
Checkpoint Inhibitor Pneumonitis: Mechanisms, Characteristics, Management Strategies, and BeyondJoshua E Reuss, Karthik Suresh, Jarushka Naidoo
Cureus|November 29, 2019
Successful Treatment of Scar Pain with Scrambler TherapyMark Yarchoan, Jarushka Naidoo, Thomas J Smith
Pageof 17